The clinical course of a patient with peripartum cardiomyopathy and hyperprolactinaemia is described. Hyperprolactinaemia may be a factor in this patient's heart failure.
Introduction
Peripartum cardiomyopathy is a rare heart muscle disorder of unknown aetiology which presents with heart failure in the last month of pregnancy or within the first 5 months ). It appears to occur more frequently in older, multiparous women and with twin pregnancies and toxaemia . This disorder tends to recur in subsequent pregnancies, sometimes with complete remission of symptoms in the intervening period. Some patients however go on to have repeated episodes of heart failure unrelated to pregnancy Stuart, 1968) . Curtarelli and Ferrari (1979) reported a case of congestive heart failure and cardiomegaly in a patient with a prolactin secreting pituitary tumour and speculate whether this is a coincidence or not. We report a patient with peripartum cardiomyopathy and hyperprolactinaemia who has been followed up for more than 13 years. The patient presented with heart failure 4 months following childbirth. Her heart failure responded promptly to digoxin and diuretics. There were two recurrences of heart failure, the first occurring in 1973 and accompanied by probable pulmonary infarction and the second in 1981. In the absence of any obvious cause of the heart failure, the above features together with the echocardiographic data strongly favour a diagnosis of peripartum cardiomyopathy. A viral myocarditis is still a possibility especially as Melvin et al. (1982) were able to diagnose myocarditis only as a result of transvenous endomyocardial biopsy in three patients with peripartum cardiomyopathy. This patient has been most reluctant to have any invasive investigations.
The coexistence of a cardiomyopathy and hyperprolactinaemia in this woman may still be a coincidence despite a previous report of cardiomyopathy in a patient with a prolactin secreting pituitary tumour (Curtarelli and Ferrari, 1979) . However, a number of observations suggest a possible role of prolactin in the pathogenesis of heart disease. Cardiomegaly and heart failure in the absence of ischaemic heart disease, hypertension, diabetes or thyroid disorder is a recognized feature of acromegaly (Pepine and Aloia, 1970; Joplin, Doyle and Lewis, 1973) . Growth hormone and prolactin have many chemical and biological similarities and hyperprolactinaemia may be found in up to 32% of patients with acromegaly (de Pablo et al., 1981) . In some acromegalic patients serum prolactin does not fall with growth hormone after pituitary surgery (Franks, Jacobs and Nabarro, 1976) . In a prospective study of heart disease in acromegaly, McGuffin et al. (1974) were unable to show a clear relationship between cardiac disease and plasma growth hormone levels. It is therefore possible that acromegalic heart disease is due to some pituitary product other than growth hormone and this product may be prolactin. Hanssen and Torjesen (1977) and Nicoll (1974) suggest that prolactin participates in sodium retention and osmoregulation.
This patient appears to have a peripartum cardiomyopathy and longstanding hyperprolactinaemia. The latter may be a factor in her heart failure as recently suggested by Curtarelli and Ferrari (1979) .
Our documentation of a second case of cardiomyopathy with hyperprolactinaemia prompts us to suggest that hyperprolactinaemia should be looked for in women of childbearing age with unexplained cardiomyopathy.
